JP2025031720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025031720A5 JP2025031720A5 JP2024204631A JP2024204631A JP2025031720A5 JP 2025031720 A5 JP2025031720 A5 JP 2025031720A5 JP 2024204631 A JP2024204631 A JP 2024204631A JP 2024204631 A JP2024204631 A JP 2024204631A JP 2025031720 A5 JP2025031720 A5 JP 2025031720A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition
- hydroxyvitamin
- optionally
- increase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802148P | 2019-02-06 | 2019-02-06 | |
| US62/802,148 | 2019-02-06 | ||
| PCT/IB2020/000089 WO2020161543A1 (en) | 2019-02-06 | 2020-02-06 | Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein |
| JP2021569596A JP2022519789A (ja) | 2019-02-06 | 2020-02-06 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569596A Division JP2022519789A (ja) | 2019-02-06 | 2020-02-06 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025031720A JP2025031720A (ja) | 2025-03-07 |
| JP2025031720A5 true JP2025031720A5 (enExample) | 2025-06-24 |
Family
ID=69903711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569596A Pending JP2022519789A (ja) | 2019-02-06 | 2020-02-06 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
| JP2024204631A Pending JP2025031720A (ja) | 2019-02-06 | 2024-11-25 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569596A Pending JP2022519789A (ja) | 2019-02-06 | 2020-02-06 | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220226351A1 (enExample) |
| EP (1) | EP3920938A1 (enExample) |
| JP (2) | JP2022519789A (enExample) |
| KR (1) | KR20210126023A (enExample) |
| CN (1) | CN113573714A (enExample) |
| AU (2) | AU2020218639A1 (enExample) |
| CA (1) | CA3128153A1 (enExample) |
| MX (1) | MX2020011741A (enExample) |
| WO (1) | WO2020161543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| PT3357496T (pt) * | 2006-06-21 | 2020-05-12 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
| PL3225243T3 (pl) * | 2007-04-25 | 2025-12-22 | Opko Renal, Llc | Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek |
| KR20190141269A (ko) * | 2007-04-25 | 2019-12-23 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| CN101668532B (zh) | 2007-04-25 | 2014-08-20 | 赛特克罗公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途 |
| CN102046812A (zh) | 2008-04-02 | 2011-05-04 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| AU2013203489B2 (en) * | 2008-07-24 | 2015-02-05 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
| CA2797537C (en) * | 2010-03-29 | 2021-11-23 | Cytochroma Inc. | Use of 25-hydroxyvitamin d compound for reducing parathyroid levels |
| KR101847947B1 (ko) * | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| EP4596045A3 (en) * | 2016-03-28 | 2025-10-15 | EirGen Pharma Ltd. | Methods of vitamin d treatment |
| CA3094915A1 (en) * | 2018-04-03 | 2019-10-10 | Opko Ireland Global Holdings, Ltd. | Use of calcifediol in bariatric surgery patients |
-
2020
- 2020-02-06 CA CA3128153A patent/CA3128153A1/en active Pending
- 2020-02-06 JP JP2021569596A patent/JP2022519789A/ja active Pending
- 2020-02-06 EP EP20713085.7A patent/EP3920938A1/en active Pending
- 2020-02-06 AU AU2020218639A patent/AU2020218639A1/en not_active Abandoned
- 2020-02-06 KR KR1020217026559A patent/KR20210126023A/ko not_active Ceased
- 2020-02-06 MX MX2020011741A patent/MX2020011741A/es unknown
- 2020-02-06 WO PCT/IB2020/000089 patent/WO2020161543A1/en not_active Ceased
- 2020-02-06 US US17/429,278 patent/US20220226351A1/en active Pending
- 2020-02-06 CN CN202080020844.6A patent/CN113573714A/zh active Pending
-
2024
- 2024-11-25 JP JP2024204631A patent/JP2025031720A/ja active Pending
-
2025
- 2025-10-30 AU AU2025259887A patent/AU2025259887A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101668532B (zh) | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途 | |
| JP2010525078A5 (enExample) | ||
| JP2017002086A5 (enExample) | ||
| JP2010525079A5 (enExample) | ||
| Krasagakis et al. | Management of severe scleroderma with long-term extracorporeal photopheresis | |
| CN100352442C (zh) | 药物组合 | |
| JP2004531468A5 (enExample) | ||
| JP2004502638A5 (enExample) | ||
| JP2025031720A5 (enExample) | ||
| JP2016179994A (ja) | イネカルシトールの新しい治療的使用 | |
| JP2020500864A5 (enExample) | ||
| Stadler et al. | Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy | |
| US6100244A (en) | Method for treating respiratory distress by sublingual administration of DNA | |
| JPWO2023078333A5 (enExample) | ||
| JPWO2022035828A5 (enExample) | ||
| NZ532994A (en) | Method for the treatment of bone disorders using a bisphosphonate regimen, risedronate in particular | |
| JP2001523724A (ja) | 運動ニューロン病および脱髄病を治療するためのシチコリン | |
| JPH0415766B2 (enExample) | ||
| JP3816545B2 (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| RU2199339C2 (ru) | Способ лечения рассеянного склероза | |
| HK40014852A (en) | Controlled release 25-hydroxyvitamin d | |
| JPWO2020161543A5 (enExample) | ||
| JP2731063B2 (ja) | 卵巣欠落によるのぼせ治療剤 | |
| JPWO2023107721A5 (enExample) | ||
| MX2023012536A (es) | Regimen de dosificacion universal de 25-hidroxivitamina d3. |